Across TCGA pan-cancer cohorts, IGLV7-46 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGLV7-46 data layer compared with 18 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher IGLV7-46 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGLV7-46 expression acts as an unfavorable survival marker.

BLCA, LUSC, and PRAD are the cancer types where IGLV7-46 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.228	0.720	.010	18	view →
LUSC	OS	Median	All	0.170	0.675	.025	15	view →
PRAD	DFS	Median	All	0.173	0.888	<.001	8	view →
LIHC	OS	Median	All	0.164	0.704	.025	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: IGLV7-46 tumor-vs-normal RNA expression · all IGLV7-46 data types